nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C9—Capecitabine—esophageal cancer	0.0357	0.665	CbGbCtD
Sitaxentan—CYP2C9—Cisplatin—esophageal cancer	0.018	0.335	CbGbCtD
Sitaxentan—Fungal infection—Methotrexate—esophageal cancer	0.00145	0.00216	CcSEcCtD
Sitaxentan—Colitis—Capecitabine—esophageal cancer	0.00144	0.00215	CcSEcCtD
Sitaxentan—Skin ulcer—Methotrexate—esophageal cancer	0.00144	0.00214	CcSEcCtD
Sitaxentan—Candida infection—Capecitabine—esophageal cancer	0.00143	0.00214	CcSEcCtD
Sitaxentan—Skin exfoliation—Capecitabine—esophageal cancer	0.00143	0.00214	CcSEcCtD
Sitaxentan—Fluid retention—Capecitabine—esophageal cancer	0.00143	0.00213	CcSEcCtD
Sitaxentan—Gingivitis—Methotrexate—esophageal cancer	0.00143	0.00213	CcSEcCtD
Sitaxentan—Abscess—Methotrexate—esophageal cancer	0.00141	0.00211	CcSEcCtD
Sitaxentan—Dry eye—Capecitabine—esophageal cancer	0.00139	0.00207	CcSEcCtD
Sitaxentan—Blood creatinine increased—Cisplatin—esophageal cancer	0.00139	0.00207	CcSEcCtD
Sitaxentan—Dehydration—Cisplatin—esophageal cancer	0.00138	0.00205	CcSEcCtD
Sitaxentan—Petechiae—Methotrexate—esophageal cancer	0.00136	0.00203	CcSEcCtD
Sitaxentan—Neoplasm—Capecitabine—esophageal cancer	0.00136	0.00203	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00135	0.00202	CcSEcCtD
Sitaxentan—Breast disorder—Cisplatin—esophageal cancer	0.00134	0.00199	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00133	0.00199	CcSEcCtD
Sitaxentan—Cramp muscle—Cisplatin—esophageal cancer	0.00133	0.00199	CcSEcCtD
Sitaxentan—Mental disability—Capecitabine—esophageal cancer	0.0013	0.00194	CcSEcCtD
Sitaxentan—Ear pain—Capecitabine—esophageal cancer	0.00128	0.00191	CcSEcCtD
Sitaxentan—Proteinuria—Methotrexate—esophageal cancer	0.00127	0.0019	CcSEcCtD
Sitaxentan—Sleep disorder—Capecitabine—esophageal cancer	0.00126	0.00188	CcSEcCtD
Sitaxentan—Protein urine present—Methotrexate—esophageal cancer	0.00126	0.00187	CcSEcCtD
Sitaxentan—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00125	0.00186	CcSEcCtD
Sitaxentan—Gastroenteritis—Capecitabine—esophageal cancer	0.00123	0.00184	CcSEcCtD
Sitaxentan—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00123	0.00183	CcSEcCtD
Sitaxentan—Abdominal discomfort—Cisplatin—esophageal cancer	0.00123	0.00183	CcSEcCtD
Sitaxentan—Deafness—Capecitabine—esophageal cancer	0.00122	0.00182	CcSEcCtD
Sitaxentan—Pancytopenia—Cisplatin—esophageal cancer	0.00121	0.00181	CcSEcCtD
Sitaxentan—Herpes simplex—Methotrexate—esophageal cancer	0.00121	0.00181	CcSEcCtD
Sitaxentan—Hepatic failure—Capecitabine—esophageal cancer	0.00121	0.00181	CcSEcCtD
Sitaxentan—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00118	0.00176	CcSEcCtD
Sitaxentan—Increased appetite—Capecitabine—esophageal cancer	0.00116	0.00173	CcSEcCtD
Sitaxentan—Menopausal symptoms—Capecitabine—esophageal cancer	0.00116	0.00172	CcSEcCtD
Sitaxentan—Inflammation—Methotrexate—esophageal cancer	0.00115	0.00172	CcSEcCtD
Sitaxentan—Renal impairment—Capecitabine—esophageal cancer	0.00115	0.00171	CcSEcCtD
Sitaxentan—Blood uric acid increased—Methotrexate—esophageal cancer	0.00114	0.0017	CcSEcCtD
Sitaxentan—Respiratory failure—Methotrexate—esophageal cancer	0.00114	0.0017	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00112	0.00168	CcSEcCtD
Sitaxentan—Arthritis—Capecitabine—esophageal cancer	0.00112	0.00167	CcSEcCtD
Sitaxentan—Renal failure—Cisplatin—esophageal cancer	0.00112	0.00167	CcSEcCtD
Sitaxentan—Pulmonary embolism—Methotrexate—esophageal cancer	0.00112	0.00167	CcSEcCtD
Sitaxentan—Myocardial infarction—Cisplatin—esophageal cancer	0.00112	0.00167	CcSEcCtD
Sitaxentan—Cardiac failure—Capecitabine—esophageal cancer	0.00112	0.00167	CcSEcCtD
Sitaxentan—Stomatitis—Cisplatin—esophageal cancer	0.00111	0.00166	CcSEcCtD
Sitaxentan—Conjunctivitis—Cisplatin—esophageal cancer	0.00111	0.00165	CcSEcCtD
Sitaxentan—Osteoarthritis—Capecitabine—esophageal cancer	0.00109	0.00163	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00109	0.00163	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00108	0.00161	CcSEcCtD
Sitaxentan—Migraine—Capecitabine—esophageal cancer	0.00107	0.0016	CcSEcCtD
Sitaxentan—Skin exfoliation—Methotrexate—esophageal cancer	0.00107	0.00159	CcSEcCtD
Sitaxentan—Vaginal infection—Methotrexate—esophageal cancer	0.00106	0.00157	CcSEcCtD
Sitaxentan—Bradycardia—Cisplatin—esophageal cancer	0.00104	0.00155	CcSEcCtD
Sitaxentan—Ataxia—Capecitabine—esophageal cancer	0.00103	0.00153	CcSEcCtD
Sitaxentan—Blood creatinine increased—Capecitabine—esophageal cancer	0.00102	0.00152	CcSEcCtD
Sitaxentan—Dehydration—Capecitabine—esophageal cancer	0.00101	0.00151	CcSEcCtD
Sitaxentan—Neoplasm—Methotrexate—esophageal cancer	0.00101	0.00151	CcSEcCtD
Sitaxentan—Urinary tract disorder—Cisplatin—esophageal cancer	0.00101	0.00151	CcSEcCtD
Sitaxentan—Liver function test abnormal—Capecitabine—esophageal cancer	0.00101	0.0015	CcSEcCtD
Sitaxentan—Urethral disorder—Cisplatin—esophageal cancer	0.001	0.0015	CcSEcCtD
Sitaxentan—Dry skin—Capecitabine—esophageal cancer	0.001	0.00149	CcSEcCtD
Sitaxentan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000996	0.00149	CcSEcCtD
Sitaxentan—Abdominal pain upper—Capecitabine—esophageal cancer	0.000996	0.00149	CcSEcCtD
Sitaxentan—Visual impairment—Cisplatin—esophageal cancer	0.000987	0.00147	CcSEcCtD
Sitaxentan—Breast disorder—Capecitabine—esophageal cancer	0.000986	0.00147	CcSEcCtD
Sitaxentan—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000982	0.00146	CcSEcCtD
Sitaxentan—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000962	0.00143	CcSEcCtD
Sitaxentan—Muscular weakness—Capecitabine—esophageal cancer	0.000962	0.00143	CcSEcCtD
Sitaxentan—Eye disorder—Cisplatin—esophageal cancer	0.000957	0.00143	CcSEcCtD
Sitaxentan—Tinnitus—Cisplatin—esophageal cancer	0.000954	0.00142	CcSEcCtD
Sitaxentan—Cardiac disorder—Cisplatin—esophageal cancer	0.00095	0.00142	CcSEcCtD
Sitaxentan—Flushing—Cisplatin—esophageal cancer	0.00095	0.00142	CcSEcCtD
Sitaxentan—Asthma—Capecitabine—esophageal cancer	0.000943	0.00141	CcSEcCtD
Sitaxentan—Immune system disorder—Cisplatin—esophageal cancer	0.000925	0.00138	CcSEcCtD
Sitaxentan—Mediastinal disorder—Cisplatin—esophageal cancer	0.000923	0.00138	CcSEcCtD
Sitaxentan—Angina pectoris—Capecitabine—esophageal cancer	0.000918	0.00137	CcSEcCtD
Sitaxentan—Bronchitis—Capecitabine—esophageal cancer	0.000907	0.00135	CcSEcCtD
Sitaxentan—Alopecia—Cisplatin—esophageal cancer	0.000905	0.00135	CcSEcCtD
Sitaxentan—Abdominal discomfort—Capecitabine—esophageal cancer	0.000904	0.00135	CcSEcCtD
Sitaxentan—Hepatic failure—Methotrexate—esophageal cancer	0.000904	0.00135	CcSEcCtD
Sitaxentan—Pancytopenia—Capecitabine—esophageal cancer	0.000895	0.00134	CcSEcCtD
Sitaxentan—Malnutrition—Cisplatin—esophageal cancer	0.000891	0.00133	CcSEcCtD
Sitaxentan—Dysuria—Capecitabine—esophageal cancer	0.000882	0.00131	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000861	0.00128	CcSEcCtD
Sitaxentan—Visual disturbance—Methotrexate—esophageal cancer	0.000857	0.00128	CcSEcCtD
Sitaxentan—Muscle spasms—Cisplatin—esophageal cancer	0.000857	0.00128	CcSEcCtD
Sitaxentan—Weight decreased—Capecitabine—esophageal cancer	0.000853	0.00127	CcSEcCtD
Sitaxentan—Hyperglycaemia—Capecitabine—esophageal cancer	0.00085	0.00127	CcSEcCtD
Sitaxentan—Infestation NOS—Capecitabine—esophageal cancer	0.000841	0.00125	CcSEcCtD
Sitaxentan—Infestation—Capecitabine—esophageal cancer	0.000841	0.00125	CcSEcCtD
Sitaxentan—Tremor—Cisplatin—esophageal cancer	0.000835	0.00125	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000829	0.00124	CcSEcCtD
Sitaxentan—Ill-defined disorder—Cisplatin—esophageal cancer	0.000827	0.00123	CcSEcCtD
Sitaxentan—Renal failure—Capecitabine—esophageal cancer	0.000826	0.00123	CcSEcCtD
Sitaxentan—Myocardial infarction—Capecitabine—esophageal cancer	0.000824	0.00123	CcSEcCtD
Sitaxentan—Anaemia—Cisplatin—esophageal cancer	0.000824	0.00123	CcSEcCtD
Sitaxentan—Jaundice—Capecitabine—esophageal cancer	0.000819	0.00122	CcSEcCtD
Sitaxentan—Stomatitis—Capecitabine—esophageal cancer	0.000819	0.00122	CcSEcCtD
Sitaxentan—Conjunctivitis—Capecitabine—esophageal cancer	0.000817	0.00122	CcSEcCtD
Sitaxentan—Osteoarthritis—Methotrexate—esophageal cancer	0.000812	0.00121	CcSEcCtD
Sitaxentan—Malaise—Cisplatin—esophageal cancer	0.000804	0.0012	CcSEcCtD
Sitaxentan—Haematuria—Capecitabine—esophageal cancer	0.000801	0.0012	CcSEcCtD
Sitaxentan—Leukopenia—Cisplatin—esophageal cancer	0.000798	0.00119	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000795	0.00119	CcSEcCtD
Sitaxentan—Epistaxis—Capecitabine—esophageal cancer	0.000793	0.00118	CcSEcCtD
Sitaxentan—Bradycardia—Capecitabine—esophageal cancer	0.000768	0.00115	CcSEcCtD
Sitaxentan—Ataxia—Methotrexate—esophageal cancer	0.000764	0.00114	CcSEcCtD
Sitaxentan—Haemoglobin—Capecitabine—esophageal cancer	0.000758	0.00113	CcSEcCtD
Sitaxentan—Rhinitis—Capecitabine—esophageal cancer	0.000757	0.00113	CcSEcCtD
Sitaxentan—Haemorrhage—Capecitabine—esophageal cancer	0.000755	0.00113	CcSEcCtD
Sitaxentan—Hepatitis—Capecitabine—esophageal cancer	0.000755	0.00113	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000753	0.00112	CcSEcCtD
Sitaxentan—Liver function test abnormal—Methotrexate—esophageal cancer	0.00075	0.00112	CcSEcCtD
Sitaxentan—Discomfort—Cisplatin—esophageal cancer	0.00075	0.00112	CcSEcCtD
Sitaxentan—Urinary tract disorder—Capecitabine—esophageal cancer	0.000745	0.00111	CcSEcCtD
Sitaxentan—Oedema peripheral—Capecitabine—esophageal cancer	0.000743	0.00111	CcSEcCtD
Sitaxentan—Urethral disorder—Capecitabine—esophageal cancer	0.00074	0.0011	CcSEcCtD
Sitaxentan—Breast disorder—Methotrexate—esophageal cancer	0.000734	0.00109	CcSEcCtD
Sitaxentan—Oedema—Cisplatin—esophageal cancer	0.000727	0.00108	CcSEcCtD
Sitaxentan—Visual impairment—Capecitabine—esophageal cancer	0.000727	0.00108	CcSEcCtD
Sitaxentan—Infection—Cisplatin—esophageal cancer	0.000723	0.00108	CcSEcCtD
Sitaxentan—Nervous system disorder—Cisplatin—esophageal cancer	0.000713	0.00106	CcSEcCtD
Sitaxentan—Thrombocytopenia—Cisplatin—esophageal cancer	0.000712	0.00106	CcSEcCtD
Sitaxentan—Tachycardia—Cisplatin—esophageal cancer	0.00071	0.00106	CcSEcCtD
Sitaxentan—Skin disorder—Cisplatin—esophageal cancer	0.000706	0.00105	CcSEcCtD
Sitaxentan—Eye disorder—Capecitabine—esophageal cancer	0.000705	0.00105	CcSEcCtD
Sitaxentan—Tinnitus—Capecitabine—esophageal cancer	0.000704	0.00105	CcSEcCtD
Sitaxentan—Asthma—Methotrexate—esophageal cancer	0.000702	0.00105	CcSEcCtD
Sitaxentan—Flushing—Capecitabine—esophageal cancer	0.0007	0.00104	CcSEcCtD
Sitaxentan—Cardiac disorder—Capecitabine—esophageal cancer	0.0007	0.00104	CcSEcCtD
Sitaxentan—Eosinophilia—Methotrexate—esophageal cancer	0.000695	0.00104	CcSEcCtD
Sitaxentan—Anorexia—Cisplatin—esophageal cancer	0.000693	0.00103	CcSEcCtD
Sitaxentan—Angiopathy—Capecitabine—esophageal cancer	0.000685	0.00102	CcSEcCtD
Sitaxentan—Immune system disorder—Capecitabine—esophageal cancer	0.000682	0.00102	CcSEcCtD
Sitaxentan—Mediastinal disorder—Capecitabine—esophageal cancer	0.00068	0.00101	CcSEcCtD
Sitaxentan—Hypotension—Cisplatin—esophageal cancer	0.00068	0.00101	CcSEcCtD
Sitaxentan—Abdominal discomfort—Methotrexate—esophageal cancer	0.000673	0.001	CcSEcCtD
Sitaxentan—Alopecia—Capecitabine—esophageal cancer	0.000667	0.000994	CcSEcCtD
Sitaxentan—Pancytopenia—Methotrexate—esophageal cancer	0.000667	0.000994	CcSEcCtD
Sitaxentan—Mental disorder—Capecitabine—esophageal cancer	0.000661	0.000986	CcSEcCtD
Sitaxentan—Malnutrition—Capecitabine—esophageal cancer	0.000657	0.00098	CcSEcCtD
Sitaxentan—Dysuria—Methotrexate—esophageal cancer	0.000656	0.000979	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000641	0.000955	CcSEcCtD
Sitaxentan—Decreased appetite—Cisplatin—esophageal cancer	0.000632	0.000943	CcSEcCtD
Sitaxentan—Muscle spasms—Capecitabine—esophageal cancer	0.000632	0.000942	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000628	0.000936	CcSEcCtD
Sitaxentan—Infestation NOS—Methotrexate—esophageal cancer	0.000626	0.000933	CcSEcCtD
Sitaxentan—Infestation—Methotrexate—esophageal cancer	0.000626	0.000933	CcSEcCtD
Sitaxentan—Pain—Cisplatin—esophageal cancer	0.000622	0.000927	CcSEcCtD
Sitaxentan—Tremor—Capecitabine—esophageal cancer	0.000615	0.000918	CcSEcCtD
Sitaxentan—Renal failure—Methotrexate—esophageal cancer	0.000615	0.000917	CcSEcCtD
Sitaxentan—Stomatitis—Methotrexate—esophageal cancer	0.00061	0.00091	CcSEcCtD
Sitaxentan—Ill-defined disorder—Capecitabine—esophageal cancer	0.000609	0.000909	CcSEcCtD
Sitaxentan—Conjunctivitis—Methotrexate—esophageal cancer	0.000608	0.000907	CcSEcCtD
Sitaxentan—Anaemia—Capecitabine—esophageal cancer	0.000607	0.000905	CcSEcCtD
Sitaxentan—Feeling abnormal—Cisplatin—esophageal cancer	0.000599	0.000894	CcSEcCtD
Sitaxentan—Haematuria—Methotrexate—esophageal cancer	0.000597	0.00089	CcSEcCtD
Sitaxentan—Malaise—Capecitabine—esophageal cancer	0.000592	0.000883	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000592	0.000883	CcSEcCtD
Sitaxentan—Epistaxis—Methotrexate—esophageal cancer	0.00059	0.00088	CcSEcCtD
Sitaxentan—Vertigo—Capecitabine—esophageal cancer	0.00059	0.00088	CcSEcCtD
Sitaxentan—Leukopenia—Capecitabine—esophageal cancer	0.000588	0.000877	CcSEcCtD
Sitaxentan—Body temperature increased—Cisplatin—esophageal cancer	0.000575	0.000857	CcSEcCtD
Sitaxentan—Haemoglobin—Methotrexate—esophageal cancer	0.000565	0.000842	CcSEcCtD
Sitaxentan—Haemorrhage—Methotrexate—esophageal cancer	0.000562	0.000838	CcSEcCtD
Sitaxentan—Hepatitis—Methotrexate—esophageal cancer	0.000562	0.000838	CcSEcCtD
Sitaxentan—Chest pain—Capecitabine—esophageal cancer	0.000559	0.000834	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000555	0.000828	CcSEcCtD
Sitaxentan—Urinary tract disorder—Methotrexate—esophageal cancer	0.000555	0.000827	CcSEcCtD
Sitaxentan—Discomfort—Capecitabine—esophageal cancer	0.000553	0.000824	CcSEcCtD
Sitaxentan—Urethral disorder—Methotrexate—esophageal cancer	0.000551	0.000821	CcSEcCtD
Sitaxentan—Dry mouth—Capecitabine—esophageal cancer	0.000547	0.000816	CcSEcCtD
Sitaxentan—Visual impairment—Methotrexate—esophageal cancer	0.000541	0.000807	CcSEcCtD
Sitaxentan—Confusional state—Capecitabine—esophageal cancer	0.000541	0.000806	CcSEcCtD
Sitaxentan—Oedema—Capecitabine—esophageal cancer	0.000536	0.000799	CcSEcCtD
Sitaxentan—Hypersensitivity—Cisplatin—esophageal cancer	0.000536	0.000799	CcSEcCtD
Sitaxentan—Infection—Capecitabine—esophageal cancer	0.000533	0.000794	CcSEcCtD
Sitaxentan—Nervous system disorder—Capecitabine—esophageal cancer	0.000526	0.000784	CcSEcCtD
Sitaxentan—Eye disorder—Methotrexate—esophageal cancer	0.000525	0.000783	CcSEcCtD
Sitaxentan—Thrombocytopenia—Capecitabine—esophageal cancer	0.000525	0.000783	CcSEcCtD
Sitaxentan—Tinnitus—Methotrexate—esophageal cancer	0.000524	0.000781	CcSEcCtD
Sitaxentan—Tachycardia—Capecitabine—esophageal cancer	0.000523	0.00078	CcSEcCtD
Sitaxentan—Asthenia—Cisplatin—esophageal cancer	0.000522	0.000778	CcSEcCtD
Sitaxentan—Cardiac disorder—Methotrexate—esophageal cancer	0.000521	0.000777	CcSEcCtD
Sitaxentan—Skin disorder—Capecitabine—esophageal cancer	0.000521	0.000777	CcSEcCtD
Sitaxentan—Anorexia—Capecitabine—esophageal cancer	0.000511	0.000762	CcSEcCtD
Sitaxentan—Angiopathy—Methotrexate—esophageal cancer	0.00051	0.00076	CcSEcCtD
Sitaxentan—Immune system disorder—Methotrexate—esophageal cancer	0.000507	0.000757	CcSEcCtD
Sitaxentan—Mediastinal disorder—Methotrexate—esophageal cancer	0.000506	0.000755	CcSEcCtD
Sitaxentan—Hypotension—Capecitabine—esophageal cancer	0.000501	0.000747	CcSEcCtD
Sitaxentan—Diarrhoea—Cisplatin—esophageal cancer	0.000498	0.000742	CcSEcCtD
Sitaxentan—Alopecia—Methotrexate—esophageal cancer	0.000496	0.00074	CcSEcCtD
Sitaxentan—Mental disorder—Methotrexate—esophageal cancer	0.000492	0.000734	CcSEcCtD
Sitaxentan—Malnutrition—Methotrexate—esophageal cancer	0.000489	0.000729	CcSEcCtD
Sitaxentan—Insomnia—Capecitabine—esophageal cancer	0.000485	0.000723	CcSEcCtD
Sitaxentan—Dyspepsia—Capecitabine—esophageal cancer	0.000472	0.000704	CcSEcCtD
Sitaxentan—Decreased appetite—Capecitabine—esophageal cancer	0.000466	0.000695	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000463	0.00069	CcSEcCtD
Sitaxentan—Vomiting—Cisplatin—esophageal cancer	0.000462	0.00069	CcSEcCtD
Sitaxentan—Fatigue—Capecitabine—esophageal cancer	0.000462	0.000689	CcSEcCtD
Sitaxentan—Rash—Cisplatin—esophageal cancer	0.000459	0.000684	CcSEcCtD
Sitaxentan—Constipation—Capecitabine—esophageal cancer	0.000458	0.000684	CcSEcCtD
Sitaxentan—Pain—Capecitabine—esophageal cancer	0.000458	0.000684	CcSEcCtD
Sitaxentan—Dermatitis—Cisplatin—esophageal cancer	0.000458	0.000683	CcSEcCtD
Sitaxentan—Ill-defined disorder—Methotrexate—esophageal cancer	0.000454	0.000677	CcSEcCtD
Sitaxentan—Anaemia—Methotrexate—esophageal cancer	0.000452	0.000674	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—ADCYAP1—esophageal cancer	0.000443	0.00161	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PDE4D—esophageal cancer	0.000442	0.0016	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Capecitabine—esophageal cancer	0.000442	0.000659	CcSEcCtD
Sitaxentan—Malaise—Methotrexate—esophageal cancer	0.000441	0.000658	CcSEcCtD
Sitaxentan—Vertigo—Methotrexate—esophageal cancer	0.000439	0.000655	CcSEcCtD
Sitaxentan—Leukopenia—Methotrexate—esophageal cancer	0.000438	0.000653	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000435	0.00158	CbGpPWpGaD
Sitaxentan—Nausea—Cisplatin—esophageal cancer	0.000432	0.000644	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000429	0.00156	CbGpPWpGaD
Sitaxentan—Urticaria—Capecitabine—esophageal cancer	0.000426	0.000635	CcSEcCtD
Sitaxentan—Body temperature increased—Capecitabine—esophageal cancer	0.000424	0.000632	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000423	0.00154	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GNG7—esophageal cancer	0.00042	0.00152	CbGpPWpGaD
Sitaxentan—Chest pain—Methotrexate—esophageal cancer	0.000416	0.000621	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000413	0.000617	CcSEcCtD
Sitaxentan—Discomfort—Methotrexate—esophageal cancer	0.000411	0.000613	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000409	0.00148	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ELMO1—esophageal cancer	0.000408	0.00148	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL2—esophageal cancer	0.000408	0.00148	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000406	0.00147	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—WWOX—esophageal cancer	0.000405	0.00147	CbGpPWpGaD
Sitaxentan—Confusional state—Methotrexate—esophageal cancer	0.000402	0.0006	CcSEcCtD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000401	0.00145	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.0004	0.00145	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKAP13—esophageal cancer	0.000399	0.00145	CbGpPWpGaD
Sitaxentan—Infection—Methotrexate—esophageal cancer	0.000396	0.000591	CcSEcCtD
Sitaxentan—Hypersensitivity—Capecitabine—esophageal cancer	0.000395	0.000589	CcSEcCtD
Sitaxentan—Nervous system disorder—Methotrexate—esophageal cancer	0.000391	0.000584	CcSEcCtD
Sitaxentan—Thrombocytopenia—Methotrexate—esophageal cancer	0.000391	0.000583	CcSEcCtD
Sitaxentan—Skin disorder—Methotrexate—esophageal cancer	0.000388	0.000578	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000387	0.0014	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FKBP1A—esophageal cancer	0.000385	0.0014	CbGpPWpGaD
Sitaxentan—Asthenia—Capecitabine—esophageal cancer	0.000385	0.000574	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—ALDH2—esophageal cancer	0.000384	0.00139	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000382	0.00139	CbGpPWpGaD
Sitaxentan—Anorexia—Methotrexate—esophageal cancer	0.00038	0.000567	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—ANXA1—esophageal cancer	0.000379	0.00137	CbGpPWpGaD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000377	0.00137	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—WIF1—esophageal cancer	0.000377	0.00137	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000374	0.00135	CbGpPWpGaD
Sitaxentan—Hypotension—Methotrexate—esophageal cancer	0.000373	0.000556	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL2—esophageal cancer	0.00037	0.00134	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—SST—esophageal cancer	0.000369	0.00134	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000368	0.00133	CbGpPWpGaD
Sitaxentan—Diarrhoea—Capecitabine—esophageal cancer	0.000367	0.000547	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GSTT1—esophageal cancer	0.000365	0.00132	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PDE4D—esophageal cancer	0.000365	0.00132	CbGpPWpGaD
Sitaxentan—Insomnia—Methotrexate—esophageal cancer	0.000361	0.000538	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—CYP2A6—esophageal cancer	0.000361	0.00131	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GHRL—esophageal cancer	0.000359	0.0013	CbGpPWpGaD
Sitaxentan—Somnolence—Methotrexate—esophageal cancer	0.000355	0.000529	CcSEcCtD
Sitaxentan—Dizziness—Capecitabine—esophageal cancer	0.000355	0.000529	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000352	0.00128	CbGpPWpGaD
Sitaxentan—Dyspepsia—Methotrexate—esophageal cancer	0.000351	0.000524	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.00035	0.00127	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CSNK1A1—esophageal cancer	0.000348	0.00126	CbGpPWpGaD
Sitaxentan—Decreased appetite—Methotrexate—esophageal cancer	0.000347	0.000517	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GNG7—esophageal cancer	0.000347	0.00126	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000345	0.000514	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—ANXA1—esophageal cancer	0.000344	0.00125	CbGpPWpGaD
Sitaxentan—Fatigue—Methotrexate—esophageal cancer	0.000344	0.000513	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—PTGS1—esophageal cancer	0.000342	0.00124	CbGpPWpGaD
Sitaxentan—Pain—Methotrexate—esophageal cancer	0.000341	0.000509	CcSEcCtD
Sitaxentan—Vomiting—Capecitabine—esophageal cancer	0.000341	0.000508	CcSEcCtD
Sitaxentan—Rash—Capecitabine—esophageal cancer	0.000338	0.000504	CcSEcCtD
Sitaxentan—Dermatitis—Capecitabine—esophageal cancer	0.000338	0.000504	CcSEcCtD
Sitaxentan—Headache—Capecitabine—esophageal cancer	0.000336	0.000501	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—SST—esophageal cancer	0.000335	0.00121	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000333	0.00121	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000329	0.00119	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000329	0.00119	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000329	0.00119	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Methotrexate—esophageal cancer	0.000329	0.00049	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000328	0.00119	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GHRL—esophageal cancer	0.000326	0.00118	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—XIAP—esophageal cancer	0.000325	0.00118	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PFN1—esophageal cancer	0.000325	0.00118	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000321	0.00116	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.00032	0.00116	CbGpPWpGaD
Sitaxentan—Nausea—Capecitabine—esophageal cancer	0.000318	0.000475	CcSEcCtD
Sitaxentan—Urticaria—Methotrexate—esophageal cancer	0.000317	0.000473	CcSEcCtD
Sitaxentan—Body temperature increased—Methotrexate—esophageal cancer	0.000315	0.00047	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000312	0.00113	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00031	0.00112	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CTNNA1—esophageal cancer	0.000307	0.00111	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL2—esophageal cancer	0.000306	0.00111	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000305	0.0011	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.0003	0.00109	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Methotrexate—esophageal cancer	0.000294	0.000438	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—ELMO1—esophageal cancer	0.000292	0.00106	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP1B1—esophageal cancer	0.000291	0.00105	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000287	0.00104	CbGpPWpGaD
Sitaxentan—Asthenia—Methotrexate—esophageal cancer	0.000286	0.000427	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000286	0.00104	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PSME2—esophageal cancer	0.000285	0.00104	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PSME1—esophageal cancer	0.000285	0.00104	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKAP13—esophageal cancer	0.000285	0.00103	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ANXA1—esophageal cancer	0.000284	0.00103	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000283	0.00103	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000281	0.00102	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000279	0.00101	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SST—esophageal cancer	0.000276	0.001	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP19A1—esophageal cancer	0.000274	0.000992	CbGpPWpGaD
Sitaxentan—Diarrhoea—Methotrexate—esophageal cancer	0.000273	0.000407	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00027	0.000978	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOTCH3—esophageal cancer	0.000269	0.000977	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GHRL—esophageal cancer	0.000269	0.000977	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000265	0.000962	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FBXW7—esophageal cancer	0.000265	0.000961	CbGpPWpGaD
Sitaxentan—Dizziness—Methotrexate—esophageal cancer	0.000264	0.000394	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000263	0.000955	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000262	0.000949	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PDE4D—esophageal cancer	0.000261	0.000947	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000256	0.000928	CbGpPWpGaD
Sitaxentan—Vomiting—Methotrexate—esophageal cancer	0.000254	0.000378	CcSEcCtD
Sitaxentan—Rash—Methotrexate—esophageal cancer	0.000252	0.000375	CcSEcCtD
Sitaxentan—Dermatitis—Methotrexate—esophageal cancer	0.000251	0.000375	CcSEcCtD
Sitaxentan—Headache—Methotrexate—esophageal cancer	0.00025	0.000373	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000249	0.000904	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GNG7—esophageal cancer	0.000248	0.0009	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000246	0.000892	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOTCH2—esophageal cancer	0.000242	0.000876	CbGpPWpGaD
Sitaxentan—Nausea—Methotrexate—esophageal cancer	0.000237	0.000354	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—XIAP—esophageal cancer	0.000233	0.000844	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000231	0.000837	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CTNNA1—esophageal cancer	0.00022	0.000798	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.00022	0.000796	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL2—esophageal cancer	0.000219	0.000793	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000217	0.000787	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TGFBR2—esophageal cancer	0.000214	0.000777	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000206	0.000746	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PSME2—esophageal cancer	0.000204	0.000741	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PSME1—esophageal cancer	0.000204	0.000741	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ANXA1—esophageal cancer	0.000203	0.000737	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SMAD4—esophageal cancer	0.000203	0.000736	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SST—esophageal cancer	0.000198	0.000717	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH3—esophageal cancer	0.000193	0.000699	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GHRL—esophageal cancer	0.000193	0.000699	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FBXW7—esophageal cancer	0.00019	0.000688	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.00019	0.000687	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000175	0.000634	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH2—esophageal cancer	0.000173	0.000627	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000173	0.000627	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000173	0.000626	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HIF1A—esophageal cancer	0.000166	0.000602	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000165	0.0006	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000164	0.000596	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000162	0.000588	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KDR—esophageal cancer	0.000159	0.000576	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TGFBR2—esophageal cancer	0.000153	0.000556	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000151	0.000547	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOTCH1—esophageal cancer	0.00015	0.000542	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—BLVRB—esophageal cancer	0.000147	0.000533	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC52A3—esophageal cancer	0.000147	0.000533	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SMAD4—esophageal cancer	0.000145	0.000527	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CREBBP—esophageal cancer	0.000136	0.000492	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000134	0.000486	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000134	0.000486	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—esophageal cancer	0.000133	0.000483	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000131	0.000476	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000127	0.000462	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC10A2—esophageal cancer	0.000125	0.000453	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CA1—esophageal cancer	0.000125	0.000453	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NOS3—esophageal cancer	0.000121	0.00044	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.00012	0.000434	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HIF1A—esophageal cancer	0.000119	0.000431	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PIK3CA—esophageal cancer	0.000116	0.000419	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CA2—esophageal cancer	0.000114	0.000414	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000114	0.000413	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CA1—esophageal cancer	0.000114	0.000413	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KDR—esophageal cancer	0.000114	0.000412	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ERBB2—esophageal cancer	0.000114	0.000412	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000112	0.000405	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOTCH1—esophageal cancer	0.000107	0.000388	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PLCE1—esophageal cancer	0.000106	0.000385	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ADH7—esophageal cancer	0.000106	0.000385	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000105	0.000381	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CA2—esophageal cancer	0.000104	0.000378	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000102	0.000369	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—esophageal cancer	0.0001	0.000364	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1A—esophageal cancer	9.7e-05	0.000352	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CREBBP—esophageal cancer	9.7e-05	0.000352	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ADH7—esophageal cancer	9.69e-05	0.000351	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PLCE1—esophageal cancer	9.69e-05	0.000351	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	9.58e-05	0.000347	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—esophageal cancer	9.53e-05	0.000346	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ADH1B—esophageal cancer	9.32e-05	0.000338	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EP300—esophageal cancer	9.23e-05	0.000335	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—PIK3CA—esophageal cancer	9.11e-05	0.00033	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TYMP—esophageal cancer	8.9e-05	0.000323	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC52A3—esophageal cancer	8.84e-05	0.000321	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—BLVRB—esophageal cancer	8.84e-05	0.000321	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NOS3—esophageal cancer	8.69e-05	0.000315	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP26A1—esophageal cancer	8.66e-05	0.000314	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ADH1B—esophageal cancer	8.5e-05	0.000308	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALOX15—esophageal cancer	8.44e-05	0.000306	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PIK3CA—esophageal cancer	8.28e-05	0.0003	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB2—esophageal cancer	8.13e-05	0.000295	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TYMP—esophageal cancer	8.12e-05	0.000294	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTO1—esophageal cancer	8.05e-05	0.000292	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TPI1—esophageal cancer	8.05e-05	0.000292	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—esophageal cancer	8.05e-05	0.000292	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP26A1—esophageal cancer	7.9e-05	0.000286	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—esophageal cancer	7.87e-05	0.000285	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALDOB—esophageal cancer	7.72e-05	0.00028	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALOX15—esophageal cancer	7.7e-05	0.000279	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CA1—esophageal cancer	7.51e-05	0.000273	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	7.51e-05	0.000273	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GAPDH—esophageal cancer	7.43e-05	0.00027	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CRABP1—esophageal cancer	7.36e-05	0.000267	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTO1—esophageal cancer	7.34e-05	0.000266	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TPI1—esophageal cancer	7.34e-05	0.000266	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—esophageal cancer	7.18e-05	0.00026	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALDOB—esophageal cancer	7.04e-05	0.000255	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNG7—esophageal cancer	7.01e-05	0.000254	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1A—esophageal cancer	6.95e-05	0.000252	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CA2—esophageal cancer	6.87e-05	0.000249	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PIK3CA—esophageal cancer	6.83e-05	0.000248	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GAPDH—esophageal cancer	6.78e-05	0.000246	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CRABP1—esophageal cancer	6.72e-05	0.000244	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EP300—esophageal cancer	6.61e-05	0.00024	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—esophageal cancer	6.61e-05	0.00024	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ALDH2—esophageal cancer	6.56e-05	0.000238	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PLCE1—esophageal cancer	6.39e-05	0.000232	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ADH7—esophageal cancer	6.39e-05	0.000232	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNG7—esophageal cancer	6.39e-05	0.000232	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTT1—esophageal cancer	6.24e-05	0.000226	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP2A6—esophageal cancer	6.17e-05	0.000224	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.15e-05	0.000223	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ALDH2—esophageal cancer	5.99e-05	0.000217	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ENO1—esophageal cancer	5.85e-05	0.000212	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS1—esophageal cancer	5.85e-05	0.000212	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PSME2—esophageal cancer	5.77e-05	0.000209	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PSME1—esophageal cancer	5.77e-05	0.000209	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—esophageal cancer	5.76e-05	0.000209	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTT1—esophageal cancer	5.69e-05	0.000206	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—esophageal cancer	5.63e-05	0.000204	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP2A6—esophageal cancer	5.63e-05	0.000204	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	5.61e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ADH1B—esophageal cancer	5.6e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TYMP—esophageal cancer	5.35e-05	0.000194	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ENO1—esophageal cancer	5.33e-05	0.000193	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS1—esophageal cancer	5.33e-05	0.000193	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PSME1—esophageal cancer	5.26e-05	0.000191	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PSME2—esophageal cancer	5.26e-05	0.000191	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	5.21e-05	0.000189	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALOX15—esophageal cancer	5.08e-05	0.000184	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.03e-05	0.000183	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP1B1—esophageal cancer	4.97e-05	0.00018	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PIK3CA—esophageal cancer	4.89e-05	0.000177	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TPI1—esophageal cancer	4.84e-05	0.000176	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTO1—esophageal cancer	4.84e-05	0.000176	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—esophageal cancer	4.73e-05	0.000172	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP19A1—esophageal cancer	4.68e-05	0.00017	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALDOB—esophageal cancer	4.64e-05	0.000168	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	4.59e-05	0.000166	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP1B1—esophageal cancer	4.54e-05	0.000165	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GAPDH—esophageal cancer	4.47e-05	0.000162	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CRABP1—esophageal cancer	4.43e-05	0.000161	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HMOX1—esophageal cancer	4.27e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP19A1—esophageal cancer	4.26e-05	0.000155	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNG7—esophageal cancer	4.21e-05	0.000153	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.19e-05	0.000152	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCB1—esophageal cancer	4.1e-05	0.000149	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.95e-05	0.000143	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HMOX1—esophageal cancer	3.89e-05	0.000141	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.82e-05	0.000138	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.75e-05	0.000136	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCB1—esophageal cancer	3.74e-05	0.000135	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.71e-05	0.000135	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS1—esophageal cancer	3.52e-05	0.000128	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ENO1—esophageal cancer	3.52e-05	0.000128	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PSME2—esophageal cancer	3.47e-05	0.000126	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PSME1—esophageal cancer	3.47e-05	0.000126	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.1e-05	0.000112	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.99e-05	0.000108	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.82e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.81e-05	0.000102	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CREBBP—esophageal cancer	2.74e-05	9.93e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.57e-05	9.31e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.5e-05	9.05e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.46e-05	8.93e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NOS3—esophageal cancer	2.45e-05	8.89e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—esophageal cancer	2.24e-05	8.13e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NOS3—esophageal cancer	2.24e-05	8.11e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.04e-05	7.41e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—EP300—esophageal cancer	1.86e-05	6.76e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—EP300—esophageal cancer	1.7e-05	6.17e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.65e-05	5.97e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NOS3—esophageal cancer	1.47e-05	5.35e-05	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.38e-05	5e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.35e-05	4.89e-05	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.26e-05	4.56e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—EP300—esophageal cancer	1.12e-05	4.07e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	8.3e-06	3.01e-05	CbGpPWpGaD
